EOM Pharmaceuticals Holdings, Inc. (IMUC)
Develops experimental drugs to treat cancer, HIV, eye diseases, and inflammatory conditions.
$0.24+0.14%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+137.9%
The outlook
IMUC is trading above both its 50- and 200-day moving averages, positioning it in the upper half of its 52-week range. The stock carries a bullish sentiment score of 84/100 among observers. With a trailing P/E of 0.0, traditional valuation metrics don't apply here—typical for pre-revenue or unprofitable biotech companies.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range66% of the way from its 52-week low to high
Market cap
$30.1M
52-wk high
$0.34
52-wk low
$0.04
50-day avg
$0.19
200-day avg
$0.16
Trailing P/E
0.0